Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Clin Microbiol Infect. 2019 Oct;25(10):1180-1185. doi: 10.1016/j.cmi.2019.03.027. Epub 2019 Apr 6.
The CDC expanded the purview of safety surveillance for ventilated patients from ventilator-associated pneumonia (VAP) to ventilator-associated events (VAE) in 2013. CDC created VAE definitions to simplify surveillance, increase objectivity, and broaden prevention efforts. Many U.S. hospitals are conducting VAE surveillance but uptake beyond the U.S. has been limited. Review of recent publications suggest three major barriers to the adoption of VAE surveillance and prevention: 1) ongoing uncertainty about VAE and concern about its limited overlap with clinically-defined VAP, 2) a paucity of studies defining risk factors for VAEs and how best to prevent VAEs, and 3) lack of emphasis on VAE surveillance and prevention by regulatory agencies. Emerging data partially address the first two points. Possible VAPs missed by VAE surveillance are associated with lower mortality rates than VAEs and have similar outcomes whether treated with ≤3 days of antibiotics or more conventional courses, suggesting VAE focuses surveillance on severe events. Potentially-modifiable VAE risk factors include deep sedation, positive fluid balance, blood transfusions, and mandatory modes of mechanical ventilation with high inspiratory pressures. Potential interventions to prevent VAEs include avoiding intubation, minimizing sedation, paired daily spontaneous awakening and breathing trials, conservative fluid management, conservative transfusion thresholds, low tidal volume ventilation, and early mobility. There are important limitations to all existing prevention studies, however, and no study has thus far has tested a VAE prevention bundle that includes all these interventions. Further work is needed to better define the clinical significance of VAPs missed by VAE surveillance, to rigorously evaluate the impact of an optimized VAE prevention bundle on VAEs and other outcomes, and to weigh whether these additional data provide adequate evidence to support mandating VAE surveillance and prevention.
美国疾病控制与预防中心(CDC)于 2013 年将通气患者的安全监测范围从呼吸机相关性肺炎(VAP)扩大到呼吸机相关性事件(VAE)。CDC 制定了 VAE 定义,以简化监测、提高客观性并扩大预防工作。许多美国医院正在进行 VAE 监测,但在美国以外的地区,这种做法的采用率有限。对最近出版物的回顾表明,采用 VAE 监测和预防存在三个主要障碍:1)对 VAE 的持续不确定性以及对其与临床定义的 VAP 有限重叠的担忧;2)缺乏定义 VAE 危险因素以及如何最佳预防 VAE 的研究;3)监管机构对 VAE 监测和预防的重视不足。新出现的数据部分解决了前两个问题。VAE 监测遗漏的潜在 VAP 与 VAE 相比死亡率较低,且无论接受≤3 天抗生素治疗还是更传统疗程治疗,结局均相似,这表明 VAE 监测重点是严重事件。潜在的可改变 VAE 危险因素包括深度镇静、正液体平衡、输血以及具有高吸气压力的强制性机械通气模式。预防 VAE 的潜在干预措施包括避免插管、最小化镇静、每日配对的自主唤醒和呼吸试验、保守的液体管理、保守的输血阈值、低潮气量通气和早期活动。然而,所有现有预防研究都存在重要的局限性,迄今为止,尚无研究测试过包含所有这些干预措施的 VAE 预防方案。需要进一步的工作来更好地定义 VAE 监测遗漏的 VAP 的临床意义,严格评估优化的 VAE 预防方案对 VAE 和其他结局的影响,并权衡这些额外的数据是否提供足够的证据来支持强制进行 VAE 监测和预防。